Kidney Innovation Accelerator (KidneyX) from ASN

ASN and U.S. Department of Health and Human Services (HHS) Sign MOU to Launch Kidney Innovation Accelerator
In order to spur the development and commercialization of innovative technologies and therapeutics in the prevention, diagnosis, and treatment of kidney diseases, ASN has signed a Memorandum of Understanding with HHS to establish the Kidney Innovation Accelerator (KidneyX).
More than 40 million Americans live with kidney diseases and more than 700,000 experience kidney failure. Despite these staggering statistics, there has been a lack of innovation due to little private investment and venture capital, misaligned public incentives, and a complex regulatory process.
KidneyX will use a three-pronged approach to bridge the gap between research and market-ready products by:
  • Providing merit-based, non-dilutive funding to promising innovators through a series of prize competitions;
  • Encouraging better coordination across HHS with agencies including the National Institutes of Health (NIH), Food and Drug Administration (FDA), and the Centers for Medicare & Medicaid Services (CMS) in order to help clarify the path toward commercialization;
  • Creating a sense of urgency to develop new therapies, much like the sense of urgency associated with other areas of healthcare including oncology, neuroscience, heart disease, and diabetes.
Image removed by sender. Kidney-x-Thumbnail.png
Kidney X Announcement Video
ASN is proud to partner with HHS in launching KidneyX in order to address barriers commonly identified as innovators look to commercialize and make new therapeutics available for patients. Our hope is that by fostering a collaborative environment among science, engineering, finance, and other disciplines, and providing competitive, non-dilutive funding, real change can be made in the fight against kidney diseases.
Mark D. Okusa, MD, FASN 
American Society of Nephrology (ASN)
The Kidney Health Initiative’s (KHI) Development of a Roadmap for Innovation in Renal Replacement Therapy (RRT)  project will serve as a foundation for KidneyX’s first round of prize funding on accelerating the commercialization of next-generation dialysis products. The KHI project aims to describe scientific, technical, and regulatory milestones needed to achieve the goal of creating a bioartificial or bioengineered alternative to dialysis as RRT.
KidneyX will accept applications for its first round of prize funding in 2018. Individuals that are interested in learning more about KidneyX are encouraged to visit, join our mailing list, and check out the HHS CTO’s new blog  on KidneyX.
American Society of Nephrology
1510 H Street, NW, Suite 800
Washington, DC 20005
Unsubscribe from these messages.
Image removed by sender. poweredByDark.png